Attached files
file | filename |
---|---|
EX-99.3 - PRESENTATION - AzurRx BioPharma, Inc. | ex99-3.htm |
EX-99.2 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-2.htm |
EX-5.1 - OPINION - AzurRx BioPharma, Inc. | ex5-1.htm |
EX-4.1 - FORM OF WARRANT - AzurRx BioPharma, Inc. | ex4-1.htm |
EX-1.1 - UNDERWRITING AGREEMENT - AzurRx BioPharma, Inc. | ex1-1.htm |
8-K - CURRENT REPORT - AzurRx BioPharma, Inc. | azrx8k_may12018.htm |
Exhibit 99.1
AzurRx BioPharma Announces Proposed Public
Offering of Common Stock
Brooklyn,
NY - (GLOBE NEWSWIRE) April 30, 2018 – AzurRx BioPharma
(NASDAQ: AZRX), (“AzurRx”
or the “Company”), announced today that it
intends to offer and sell shares of its common stock in an
underwritten public offering. AzurRx intends to use the net
proceeds from the offering primarily for research and development
expenses associated with AzurRx’s continuing clinical
development and testing of MS1819, advancing its preclinical
programs for AZX1103 and for other general corporate purposes and
capital expenditures. The offering is subject to market conditions,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
Oppenheimer
& Co. Inc. is acting as sole underwriter for the
offering.
The
securities described above are being offered by AzurRx pursuant to
a registration statement previously filed with, and declared
effective by, the Securities and Exchange Commission (SEC). A
preliminary prospectus supplement and accompanying prospectus
relating to this offering has been filed with the SEC. This press
release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction. When available, copies of
the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from
Oppenheimer & Co. Inc. Attention: Syndicate Prospectus
Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by
telephone at (212) 667-8563, or by email at EquityProspectus@opco.com.
Electronic copies of the preliminary prospectus supplement and
accompanying prospectus will also be available on the website of
the SEC at www.sec.gov.
About AzurRx
AzurRx
BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and
development of non-systemic biologics for the treatment of patients
with gastrointestinal disorders. MS1819 recombinant lipase for
exocrine pancreatic insufficiency is the company's lead development
program, and additional early stage research is being conducted for
the prevention of certain hospital-acquired infections. The company
is headquartered in Brooklyn, NY, with scientific operations based
in Langlade, France. Additional information on the company can be
found at www.azurrx.com
Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
contained in this press release are forward-looking statements,
including statements regarding the Company’s expectations on
the completion, timing and size of the proposed public offering and
the anticipated use of proceeds therefrom. In some cases, you can
identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "contemplates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these
terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including the risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed public offering, as well as risks and
uncertainties inherent in AzurRx’s business, including those
described in the company's prior press releases and in the periodic
reports it files with the SEC. The events and circumstances
reflected in the company's forward-looking statements may not be
achieved or occur and actual results could differ materially from
those projected in the forward-looking statements. Except as
required by applicable law, the company does not plan to publicly
update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise.
CONTACT:
AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn, NY 11226
Phone: 646.699.7855
www.azurrx.com
info@azurrx.com
Source: AzurRx BioPharma, Inc.